2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAllogeneic hematopoietic cell transplantAllo-HCTHematopoietic cell transplantSalvage therapyMyelodysplastic syndromeCell transplantMemorial Sloan-Kettering Cancer CenterHigh-risk myelodysplastic syndromeSecond allo-HCTSalvage treatment optionOverall response rateMedian followMedian OSVenetoclax therapyRetrospective studyCancer CenterTreatment optionsOS estimatesMyeloid leukemiaPatientsResponse rateTherapyTransplantMonths
2020
Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsPredictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.Peer-Reviewed Original ResearchRelapse-free survivalPET-CT scanTime of SCTTime of alloSCTPET-CTT-NHLBM biopsyAllo-SCTCT scanPositive PET/CT scanPredictive valueLong-term relapse-free survivalPositive PET-CT scanAllogeneic stem cell transplantPeripheral blood flow cytometryPET/CT scansIntermediate-high riskBlood flow cytometryAggressive clinical courseStem cell transplantT-cell lymphomaMajority of ptsPositive PET-CTAuto-SCTMedian follow
2013
Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaCutaneous gamma-delta T-cell lymphomaHepatosplenic T-cell lymphomaPeripheral T-cell lymphomaStem cell transplantationInitial therapyCell transplantationLymphoid neoplasmsPrimary cutaneous gamma-delta T-cell lymphomaGamma delta T-cell receptorInitiation of chemotherapySingle-center experienceAggressive clinical courseOff-label useT-cell NHLT cell receptorAdvisory CommitteeAcute GVHDAlloBMT patientsMedian followSalvage therapyAdditional therapyB symptomsFirst remission
2008
Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)
Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper D, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL). Blood 2008, 112: 3750. DOI: 10.1182/blood.v112.11.3750.3750.Peer-Reviewed Original ResearchSubcutaneous panniculitis-like T-cell lymphomaPanniculitis-like T-cell lymphomaTCR gene rearrangementsT-cell lymphomaRetrospective studyDenileukin diftitoxPoor prognosisT cellsCytotoxic T-cell markersAllogeneic hematopoietic stem cellsT cell receptor expressionCytotoxic chemotherapy regimensMatched-related donorsEvidence of diseaseRare clinical entityAggressive clinical courseT-cell markersMalignant T cellsCell receptor expressionClonal TCR gene rearrangementNovel T cellAllogeneic HSCTMedian followAggressive therapyChemotherapy regimens